DGAP-News: Wacker Chemie AG
/ Key word(s): Quarterly / Interim Statement
Munich, October 28, 2021 - Wacker Chemie AG ended Q3 2021 with strong growth in sales and earnings thanks to continued high customer demand across all business divisions. Group sales totaled €1,658.6 million from July through September. That is 40 percent more than a year earlier (€1,183.1 million) and 11 percent higher versus the preceding quarter (€1,501.0 million). Whereas the coronavirus pandemic still had a negative economic impact on WACKER's business in Q3 2020, volumes grew significantly in all of the company's key customer industries in the reporting quarter. Positive product-mix effects, higher prices - especially for solar-grade polysilicon - and exchange-rate effects also lifted sales. In the first nine months of the year, Group sales came in at €4,519.2 million (9M 2020: €3,453.0 million), up 31 percent year over year. WACKER posted EBITDA of €433.7 million in Q3 2021. The operating result was more than double last year's figure (€190.8 million). Compared with the prior quarter (€326.6 million), EBITDA increased 33 percent. In addition to higher volumes and increased prices, cost savings from the Group's ongoing efficiency program had a positive effect on operating performance. On the other hand, a marked rise in prices for energy and certain raw materials dampened EBITDA. The Group's EBITDA margin was 26.1 percent for the three months from July through September 2021. A year earlier, the figure was 16.1 percent, while the prior quarter's EBITDA margin was 21.8 percent. In the first nine months of the fiscal year, Group EBITDA came to €1,006.7 million and was thus more than twice as high as the same period last year (€470.3 million). Group EBIT (earnings before interest and taxes) more than tripled year over year. EBIT for July through September 2021 came in at €342.6 million (Q3 2020: €90.6 million). The EBIT margin was 20.7 percent (Q3 2020: 7.7 percent). Compared with Q2 2021 (€233.7 million), EBIT grew 47 percent. Net income for the quarter amounted to €248.7 million (Q3 2020: €67.7 million) and earnings per share came in at €4.90 (Q3 2020: €1.30). WACKER confirmed its full-year forecast, which it raised on September 15. Full-year sales are expected to reach around €6 billion (2020: €4.69 billion) and EBITDA is likely to be between €1.2 billion and €1.4 billion (2020: €666 million). Continued high polysilicon prices and ongoing very strong demand in the chemical divisions are the reasons for these higher expectations. At the same time, higher raw-material prices and negative exchange-rate effects are dampening EBITDA. WACKER now expects this to have a negative effect of more than €400 million (previously: €300 million), which has been factored into the current outlook. "WACKER is on a very good course. We achieved record sales in the third quarter and I expect 2021 to be an excellent year for the company," said Group CEO Christian Hartel in Munich on Thursday. According to Hartel, all divisions contributed to the good Q3 figures. "Our polysilicon business has performed very well in recent months. With more and more photovoltaic installations coming on stream worldwide, demand is growing for the polysilicon we produce for highly efficient solar cells. On top of that, rising prices for solar-grade polysilicon have been beneficial for our business. Demand remains robust in the semiconductor industry as well. Today, our hyperpure polysilicon can be found in nearly half the computer chips being installed across the globe. We intend to continue building on our market position in this field. WACKER delivers the high-quality material needed for powerful solar modules and semiconductors." Hartel went on to say that, in recent months, demand had grown in the chemical divisions as well. "For years, our strategy with silicones has been to expand our range of specialty products, and that is paying off more and more. In the past quarter, we posted double-digit growth rates for silicones in all application fields, with our specialty silicones offering multiple indispensable properties," explained Hartel. "As for polymers, our position as market leader also means we are profiting from high construction activity worldwide. Our polymer products are an indispensable base material for innovative building solutions." Hartel also noted that bioengineered products were performing well. "Biotechnology is a particularly promising field for WACKER. Biologics, for example, is one segment where sales growth has been especially strong recently. Our cyclodextrins business has also expanded. These special properties of these molecules open up a wide variety of new applications. Cyclodextrins can improve the bioavailability of drugs, for instance, by enhancing their solubility." Regions Capital Expenditures and Net Cash Flow Net cash flow amounted to €425.9 million in Q3 2021 (Q3 2020: €295.5 million). Substantially higher cash inflows from operating activities were the main factor in this 44-percent increase. Employees Business Divisions Sales at WACKER POLYMERS totaled €468.8 million in the reporting quarter, 38 percent higher than a year earlier (€340.3 million). This growth was driven by significantly higher volumes - especially for dispersible polymer powders - and higher average prices for polymer products. Changes in exchange rates were another factor with a positive impact on sales. Compared with the preceding quarter (€403.5 million), sales grew 16 percent. WACKER POLYMERS reported Q3 EBITDA of €84.5 million, versus €85.2 million a year earlier. Despite a massive increase in raw-material prices, which WACKER POLYMERS is responding to with a substantial increase in its selling prices, earnings remained on par with a year earlier. Relative to the preceding quarter (€52.2 million), EBITDA climbed 62 percent. The EBITDA margin was 18.0 percent in the reporting quarter, compared with 25.0 percent a year earlier and 12.9 percent in the preceding quarter. Amid persistently rising energy, raw-material and logistics costs, the division announced in mid-October that it would raise the prices of its polymer dispersions, dispersible polymer powders and solid resins by up to 20 percent. WACKER BIOSOLUTIONS posted total sales of €78.0 million in Q3 2021, up 36 percent versus the same period last year (€57.2 million). Contract manufacturing of biologics performed particularly well, as did the cyclodextrins segment. Compared with the preceding quarter (€71.0 million), the division's sales were up 10 percent. EBITDA at WACKER BIOSOLUTIONS reached €11.4 million in the reporting quarter, up 43 percent versus a year earlier (€8.0 million). This growth was attributable not only to higher sales, but also to higher average selling prices for certain products and to the division's good cost structure. Compared with Q2 2021 (€11.2 million), EBITDA increased 2 percent. The EBITDA margin was 14.6 percent, compared with 14.0 percent a year earlier and 15.8 percent in the prior quarter. WACKER POLYSILICON generated total sales of €408.9 million in the reporting quarter, up 94 percent over the same period last year (€211.3 million). This substantial growth was due chiefly to much higher average prices for solar-grade polysilicon. Relative to the preceding quarter (€352.9 million), sales increased 16 percent. WACKER POLYSILICON's reporting-quarter EBITDA came in at €200.8 million. That was €192.9 million more than in the same period last year (€7.9 million). This strong increase was driven mainly by higher prices for solar-grade polysilicon, but the division's good cost performance and higher plant utilization rates also had a positive impact on the earnings trend. Relative to the preceding quarter (€148.7 million), EBITDA rose 35 percent. In the reporting quarter, the division's EBITDA margin was 49.1 percent, after 3.7 percent in Q3 2020 and 42.1 percent in Q2 2021. Outlook In view of the positive business trend, the company had already revised its sales and earnings forecast upward when it presented its figures for Q1 2021 and did so again on June 16. WACKER once again raised its full-year forecast on September 15, 2021, and now expects sales of around €6 billion for full-year 2021 (2020: €4.69 billion). The company had previously expected to post full-year sales of about €5.5 billion. Full-year EBITDA for 2021 is likely to come in between €1.2 billion and €1.4 billion. Previously, WACKER had expected EBITDA of between €900 million and €1.1 billion. Continued high polysilicon prices and ongoing very strong demand in the chemical divisions are the reasons for WACKER's higher business expectations for the remainder of the year. At the same time, the company anticipates that higher raw-material prices and negative exchange-rate effects will dampen EBITDA this year. WACKER now believes this will have a negative effect of more than €400 million (previously: €300 million), which has been factored into the current outlook. The company currently expects net cash flow to be clearly positive and higher than last year (previous guidance: clearly positive, on par with last year's level). The company most recently revised its full-year estimates for the EBITDA margin, ROCE and net cash flow on June 16, when it expected the full-year EBITDA margin to be substantially higher than last year and ROCE to be substantially higher than the cost of capital. Key Figures for the WACKER Group
This press release contains forward-looking statements based on assumptions and estimates of WACKER's Executive Board. Although we assume the expectations in these forward-looking statements are realistic, we cannot guarantee they will prove to be correct. The assumptions may harbor risks and uncertainties that may cause the actual figures to differ considerably from the forward-looking statements. Factors that may cause such discrepancies include, among other things, changes in the economic and business environment, variations in exchange and interest rates, the introduction of competing products, lack of acceptance for new products or services, and changes in corporate strategy. WACKER does not plan to update its forward-looking statements, nor does it assume the obligation to do so.
For further information, please contact:
28.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Wacker Chemie AG |
Hanns-Seidel-Platz 4 | |
81737 München | |
Germany | |
Phone: | 0049-89-6279-1633 |
Fax: | 0049-89-6279-2933 |
E-mail: | investor.relations@wacker.com |
Internet: | www.wacker.com |
ISIN: | DE000WCH8881 |
WKN: | WCH888 |
Indices: | MDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1244086 |
End of News | DGAP News Service |
|
1244086 28.10.2021
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.